Opinion

Video

Exploring Data Outcomes From the SUNLIGHT Trial

Author(s):

John Marshall, MD,Al B. Benson III, MD, FACP, FACCC, FASCO

Leading colorectal cancer specialists analyze the SUNLIGHT trial results, focusing on age-related efficacy data and its implications for treatment strategies.

  1. Briefly summarize the SUNLIGHT trial, evaluating TAS-102 ± bevacizumab in patients with mCRC (Prager, et al. NEJM, 2023)
    1. Dr Fakih: How does age impact efficacy and safety outcomes from the SUNLIGHT trial in mCRC? (Taieb J, et al. ASCO GI 2024. Abstract 111)
    2. Dr Benson: What is the impact of colorectal liver metastases (CRLM) in patients with mCRC treated with TAS-102 ± bevacizumab? (Tabernero J, et al. ASCO 2024. Abstract 3584.)

Related Videos
2 KOLs are featured in this series.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
5 KOLs are featured in this series.
Related Content
Cindy M. Pabon, MD
November 20th 2024

Phase 3 Trial Data Inform Advancements in Targeted Therapy for Gastric/GEJ Cancers

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Cindy M. Pabon, MD
November 18th 2024

Zolbetuximab Approval Paves Way for Precision Medicine in Gastric and GEJ Adenocarcinoma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Sebastian Kaulitzki – stock.adobe.com
November 14th 2024

2024 Updates in GI Cancer Feature FLOT Combinations, Restricted FDA Approvals by PD-L1 Expression, and More

Zolbetuximab Plus Chemotherapy in Gastric/GEJ Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
November 12th 2024

Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer